KARD · Kardigan, Inc.
$14.79
+0.54 (+3.79%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 11, 2026
The latest filing states the doubt was alleviated.
“The Company previously concluded that recurring losses, negative cash flows from operations, and limited liquidity raised substantial doubt about its ability to continue as a going concern. In June 2026, the Company completed its IPO and received net proceeds of approximately $422.4 million. Upon closing of the IPO and receipt of the associated net proceeds, the Company alleviated the substantial doubt that previously existed.”View the 10-Q filed Aug 11, 2026
Market Cap
$1.38B
Shares
93.50M
Volume · Oct 2
524.5K
Avg daily vol (3M)
456.3K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$14.79
Open$14.48
Day$14.15–15.27
Available close range$14.25–25.90
Avg vol 30d683K
Short int2.6M · 2.7% float · 6.3d
Short vol83%
DataJun 2026–Oct 2026
Filing10-Q · Aug 11
The closing range uses available history since Jun 18, 2026; less than a full year is stored.
Up next
filed Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$384.00M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+103.5%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
2.7%
Latest settlement · 6.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Limited
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
−23%
below
RSI (14)
33
neutral
MACD trend
Negative
52-week position
5%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+69 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.75% of float · ▲ +16.3% MoM · 6.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
69 holders — 13F breadth
Squeeze score
59
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
69%
annualized · 1-yr
Max drawdown
−45%
past year
ATR
8.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
−23%
Bearish
RSI (14)
33
Neutral
MACD trend
Negative
Bearish
52-week position
5%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+69 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.75% of float · ▲ +16.3% MoM · 6.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
69 holders — 13F breadth
Price context
position in its available closing range
Range low $14
Now $15 · 5%
Range high $26
vs 50-day avg -23%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KARD
this stock
Kardigan, Inc.
|
$1.38B | — | — | — | 2.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KARD | +0.0% | -28.7% | — | +0.3% | — |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +0.2% | -28.2% | — | -0.7% | — |